Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 06, 2018 06:35 ET | Source: Nightstar Therapeutics

Nightstar Therapeutics Reports First Quarter 2018 Financial Results and Acceleration of Preliminary NSR-RPGR Readout to Third Quarter 2018

Preliminary data from dose escalation study in the Phase 1/2 XIRIUS trial for X-Linked Retinitis Pigmentosa expected ahead of schedule in Q3 2018 Dose expansion study in the XIRIUS trial expected to...
May 31, 2018 06:30 ET | Source: Nightstar Therapeutics

Nightstar Therapeutics to Present at Jefferies 2018 Global Healthcare Conference

LEXINGTON, Mass. and LONDON, May 31, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal...
April 30, 2018 06:30 ET | Source: Nightstar Therapeutics

Nightstar Therapeutics to Present at the Deutsche Bank 43rd Annual Health Care Conference

LEXINGTON, Mass. and LONDON, April 30, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal...
April 23, 2018 06:30 ET | Source: Nightstar Therapeutics

Nightstar Therapeutics to Present New Data in Choroideremia at the ARVO 2018 Annual Meeting

LEXINGTON, Mass. and LONDON, April 23, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal...
April 03, 2018 17:15 ET | Source: Nightstar Therapeutics

Nightstar Therapeutics Reports 2017 Financial Results and Business Highlights

- Recent initiation of STAR phase 3 trial in Choroideremia - - Begins 2018 with a cash position over $129 million - LEXINGTON, Mass. and LONDON, April 03, 2018 (GLOBE NEWSWIRE) -- Nightstar...
March 05, 2018 06:30 ET | Source: Nightstar Therapeutics

Nightstar Therapeutics Announces Initiation of STAR Phase 3 Registrational Trial for NSR-REP1 in Choroideremia

LEXINGTON, Mass. and LONDON, March 05, 2018 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal...
December 07, 2017 06:30 ET | Source: Nightstar Therapeutics

Nightstar Therapeutics to Participate in BMO Prescriptions for Success Healthcare Conference

LEXINGTON, Mass. and LONDON, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal...
November 08, 2017 06:30 ET | Source: Nightstar Therapeutics

Nightstar Expands Pipeline with Novel Gene Therapy for the Treatment of Stargardt Disease

Fourth Gene Therapy Program Targets the Most Common Inherited Juvenile Macular Dystrophy LEXINGTON, Mass. and LONDON, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Nightstar Therapeutics (NASDAQ:NITE), a...
October 30, 2017 16:05 ET | Source: Nightstar Therapeutics

Nightstar Therapeutics to Participate in Multiple Conferences in November

LEXINGTON, Mass. and LONDON, Oct. 30, 2017 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments for rare inherited retinal...
October 02, 2017 16:05 ET | Source: Nightstar Therapeutics

Nightstar Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares

LEXINGTON, Mass. and LONDON, Oct. 02, 2017 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc (“Nightstar” or the “Company”) (NASDAQ:NITE), a clinical-stage gene therapy company developing treatments...